Non-small cell lung cancer metastatic
Information
- Disease name
- Non-small cell lung cancer metastatic
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04394624 | Active, not recruiting | Phase 2 | Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) | August 31, 2020 | September 30, 2024 |
| NCT04154956 | Active, not recruiting | Phase 3 | SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients | February 6, 2020 | August 26, 2026 |
| NCT03611738 | Active, not recruiting | Phase 1 | Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | February 1, 2019 | April 2025 |
| NCT02812667 | Active, not recruiting | Phase 1 | Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) | August 29, 2016 | June 2025 |
| NCT04619004 | Active, not recruiting | Phase 2 | HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer | February 2, 2021 | November 1, 2024 |
| NCT01656551 | Active, not recruiting | Phase 3 | MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer | August 2012 | November 2024 |
| NCT02035683 | Active, not recruiting | N/A | PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy | October 2013 | December 2024 |
| NCT01405586 | Active, not recruiting | Phase 3 | MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer | March 2011 | November 2024 |
| NCT03469960 | Active, not recruiting | Phase 3 | Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr | May 2, 2018 | December 2024 |
| NCT01966003 | Completed | Phase 3 | Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer | November 11, 2013 | July 23, 2015 |
| NCT04009122 | Completed | N/A | Evaluation of the Quality of Life of Patients With Metastatic Non-small Cell Lung Cancer With Supplementary Therapy With IGEN-0206 | June 11, 2019 | December 14, 2022 |
| NCT03727477 | Completed | Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib | February 1, 2019 | October 12, 2020 | |
| NCT02117167 | Completed | Phase 2 | SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | April 23, 2014 | December 2023 |
| NCT02843815 | Completed | Phase 1/Phase 2 | Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer | July 1, 2016 | July 1, 2019 |
| NCT04793815 | Completed | N/A | Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE) | May 1, 2021 | June 27, 2023 |
| NCT04749602 | Completed | Phase 2 | Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion. | August 10, 2020 | March 1, 2023 |
| NCT01473563 | Completed | Phase 2 | A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) | December 2011 | September 2013 |
| NCT01523340 | Completed | A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response | September 2011 | November 2017 | |
| NCT01703091 | Completed | Phase 2 | A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer | December 2012 | July 2016 |
| NCT01705184 | Completed | Phase 2 | Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer. | December 2012 | October 2017 |
| NCT01848613 | Completed | Phase 4 | Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC | October 2012 | May 2018 |
| NCT01935154 | Completed | Phase 2 | Efficacy Study of Vx001 Vaccine in NSCLC Patients | August 2012 | January 2017 |
| NCT02959619 | Completed | Phase 1 | Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK | March 6, 2017 | April 23, 2020 |
| NCT00701558 | Completed | Phase 2 | A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer | August 2008 | December 2010 |
| NCT03007875 | Completed | Phase 1/Phase 2 | High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer | December 1, 2016 | September 1, 2019 |
| NCT02314364 | Completed | Phase 2 | A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC | December 2014 | November 2022 |
| NCT06045767 | Not yet recruiting | Phase 2 | T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer | June 2024 | January 2029 |
| NCT06106802 | Not yet recruiting | Phase 2 | Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment | February 2, 2024 | September 30, 2029 |
| NCT06127940 | Recruiting | Phase 1 | K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation | October 15, 2023 | January 1, 2026 |
| NCT02622581 | Recruiting | Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients | December 2015 | December 2027 | |
| NCT02922764 | Recruiting | Phase 1 | A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer | November 2016 | May 2024 |
| NCT04163432 | Recruiting | Phase 2 | Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC | June 16, 2020 | February 15, 2026 |
| NCT04563338 | Recruiting | Phase 2 | An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) | June 4, 2021 | December 5, 2024 |
| NCT04868877 | Recruiting | Phase 1/Phase 2 | A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors | April 28, 2021 | April 2025 |
| NCT04923945 | Recruiting | Phase 3 | Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients | August 19, 2021 | December 2024 |
| NCT04994795 | Recruiting | Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer | August 21, 2021 | February 2025 | |
| NCT05265650 | Recruiting | Phase 1/Phase 2 | Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC | June 13, 2022 | June 2024 |
| NCT05472467 | Recruiting | Phase 2 | Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer | December 21, 2021 | December 20, 2023 |
| NCT05638425 | Recruiting | Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases | December 31, 2021 | December 31, 2025 | |
| NCT05689671 | Recruiting | Phase 4 | Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma | December 6, 2023 | October 2026 |
| NCT05800223 | Recruiting | Phase 3 | Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer | January 1, 2023 | December 2028 |
| NCT05889247 | Recruiting | N/A | Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer | July 28, 2023 | June 2032 |
| NCT05919264 | Recruiting | Phase 1/Phase 2 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | May 19, 2023 | August 31, 2027 |
| NCT06083870 | Recruiting | Phase 1 | An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC | December 13, 2023 | July 2026 |
| NCT01320501 | Suspended | Phase 4 | Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer | October 2009 | August 2016 |
| NCT01356303 | Suspended | Phase 2 | Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer | March 2009 | August 2016 |
| NCT02299765 | Terminated | Phase 4 | Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC | December 2014 | October 2017 |
| NCT01752023 | Terminated | Phase 2 | A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC. | March 2013 | April 2014 |
| NCT03386929 | Terminated | Phase 1/Phase 2 | Survival Prolongation by Rationale Innovative Genomics | November 29, 2017 | December 29, 2022 |
| NCT02019979 | Terminated | Phase 2 | Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) | December 2013 | December 2016 |
| NCT03445000 | Terminated | Phase 2 | ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer | November 6, 2018 | March 31, 2021 |
| NCT02228421 | Terminated | Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients | February 2015 | March 2020 | |
| NCT03477474 | Terminated | Registry of Guardant360® Use and Outcomes In People With Advanced Cancer | April 6, 2018 | September 1, 2019 | |
| NCT02162537 | Terminated | Phase 3 | Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases | December 2013 | January 2019 |
| NCT01348126 | Terminated | Phase 2/Phase 3 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer | May 2011 | October 2015 |
| NCT01574300 | Terminated | Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network | November 2010 | March 1, 2019 | |
| NCT01798485 | Terminated | Phase 3 | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC | April 2013 | December 2015 |
| NCT01471964 | Terminated | Phase 1/Phase 2 | Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer | October 20, 2011 | April 10, 2018 |
| NCT01380795 | Terminated | Early Phase 1 | Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas | March 9, 2011 | June 2019 |
| NCT04069936 | Terminated | Phase 2 | Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC | October 15, 2019 | November 30, 2021 |
| NCT02443337 | Terminated | Phase 2 | A Study of LY3023414 and Necitumumab in Squamous Lung Cancer | July 2015 | September 2017 |
| NCT02376699 | Terminated | Phase 1 | Safety Study of SEA-CD40 in Cancer Patients | February 28, 2015 | April 14, 2023 |
| NCT03732274 | Unknown status | Phase 1/Phase 2 | Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC | December 21, 2018 | December 30, 2022 |
| NCT03956641 | Unknown status | N/A | Evolution of the Physical Condition in Treated Cancer Patients | September 17, 2019 | June 1, 2021 |
| NCT04082182 | Unknown status | Phase 1 | MIDRIX4-LUNG Dendritic Cell Vaccine in Patients With Metastatic Non-small Cell Lung Cancer | August 26, 2019 | December 31, 2021 |
| NCT04331626 | Unknown status | Phase 4 | Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC | April 2020 | April 2023 |
| NCT04504071 | Unknown status | Phase 2 | Dacomitinib in Lung Cancer With Uncommon EGFR Mutations | December 8, 2020 | December 2022 |
| NCT04646824 | Unknown status | Phase 2 | Almonertinib With Chemotherapy in mEGFR NSCLC | November 19, 2020 | November 25, 2022 |
| NCT04836728 | Unknown status | Phase 2 | Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer | April 1, 2021 | December 1, 2023 |
| NCT05407155 | Unknown status | N/A | Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer | June 2022 | June 2024 |
| NCT03240549 | Unknown status | Phase 2 | Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease | August 2017 | September 30, 2019 |
| NCT03424980 | Unknown status | A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors | December 31, 2017 | April 30, 2018 | |
| NCT03656094 | Unknown status | Phase 2 | Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors | November 1, 2018 | November 1, 2021 |
| NCT02041468 | Unknown status | Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients | January 2014 | June 2018 | |
| NCT03916913 | Unknown status | N/A | TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC | January 1, 2019 | January 1, 2023 |